TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00129129

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ActHIB
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ActHIB
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix
Description: Primary phase: 3 IM doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Primary phase: 3 IM doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Primary phase: 3 IM doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: Primary phase: 3 IM doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix
Description: Primary phase: 3 IM doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Primary phase: 3 IM doses Booster phase: 1 IM dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menomune
Description: Primary phase: 1 SC dose
Study: NCT00924872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheelchair skills training
Description: Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
Study: NCT04264468

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy
Description: This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the Mammaprint technology analysis of patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in the tumor tissues and evaluated the accuracy and sensitivity of the Mammaprint test for the efficacy of neoadjuvant chemotherapy
Study: NCT01758380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
Study: NCT02056327

Intervention type: DEVICE
Intervention: A novel monitoring suite of sensors will be inserted into the standard oral device.
Study: NCT04025229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT exercise
Description: High intensity interval training (4 to 6 sessions) prior to surgery
Study: NCT01758380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Gliclazide
Description: Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Vildagliptin
Description: Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
Study: NCT01094691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Allograft Biopsy
Description: A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
Study: NCT00975949

Intervention type: OTHER
Intervention: Survey
Description: Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.

Intervention type: OTHER
Intervention: Survey
Description: Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
Study: NCT01992211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
Study: NCT01992211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Study: NCT01042561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3 placebo
Description: Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
Study: NCT00669253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er: YAG Laser
Description: Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment 1(ultrasonic and manual means)
Description: Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment 2 (ultrasonic and manual means)
Description: Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core
Description: The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
Study: NCT04006015

Intervention type: OTHER
Intervention: No intervention being delivered.
Description: No interventions are being delivered.

Intervention type: OTHER
Intervention: No intervention being delivered.
Description: No interventions are being delivered.

Intervention type: OTHER
Intervention: No intervention being delivered.
Description: No interventions are being delivered.
Study: NCT01410721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Intervention
Description: Baseline training and follow-up at two months and four months.
Study: NCT01992211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
Study: NCT01410721

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Rehabilitation Control Intervention
Description: Baseline training and follow-up at two months and four months.
Study: NCT02245620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
Study: NCT00833599

Intervention type: DRUG
Intervention: NIRFLI with ICG
Description: We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
Study: NCT01992211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
Study: NCT05063175

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.
Study: NCT05063175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy Protocol
Description: The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTog orthotic undergarment with its strapping system
Description: TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online gym
Description: Participants will receive access to online exercise videos.
Study: NCT03039322

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Golgi Protein 73
Description: Serum test
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications
Study: NCT01992211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCWP_C003
Description: Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
Study: NCT01192568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel
Study: NCT01022424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: Repeated oral administration at doses of 15 mg twice daily (morning and evening)
Study: NCT00133666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Communication Education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Education
Study: NCT03010280

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Balanced high-protein formula
Description: Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
Study: NCT04313270

Intervention type: DRUG
Intervention: Evolocumab
Description: 12 weeks of treatment with Evolocumab
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications
Study: NCT03416127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.
Study: NCT01971008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo binder
Study: NCT01462617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2269557 matching placebo
Description: Study Drug
Study: NCT00495625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
Study: NCT03131440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App notifications
Description: Participants will receive motivational app notifications
Study: NCT01012544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
Study: NCT01712425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0-24 week prime/boost regimen
Description: ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0-8 week prime/boost regimen
Description: ChAdV63.HIVcons (5x10\^10 vp) and MVA.HIVconsv (2x10\^8 pfu) HIV-1 vaccines, delivered intramuscularly